Bass Denied Trials In Acorda Patent Challenges; Shares Soar
This article was originally published in Scrip
Executive Summary
The US Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) on Aug. 24 denied two so-called inter partes review (IPR) petitions filed by Kyle Bass – the hedge fund manager the drug industry loves to hate – and his Coalition for Affordable Drugs, which sought to invalidate patents held by Acorda Therapeutics for its FDA-approved multiple sclerosis drug Ampyra (dalfampridine).